These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33443332)

  • 21. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
    Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
    Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
    Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
    Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal prandial timing of bolus insulin in diabetes management: a review.
    Slattery D; Amiel SA; Choudhary P
    Diabet Med; 2018 Mar; 35(3):306-316. PubMed ID: 29044708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin lispro: a review of its use in the management of diabetes mellitus.
    Simpson D; McCormack PL; Keating GM; Lyseng-Williamson KA
    Drugs; 2007; 67(3):407-34. PubMed ID: 17335298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
    Meiffren G; Herbrand T; Anastassiadis E; Klein O; DeVries JH; Heise T; Alluis B; Mégret C; Gaudier M; Soula O; Plum-Mörschel L
    Diabetes Obes Metab; 2019 Jul; 21(7):1570-1575. PubMed ID: 30828929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
    Home PD
    Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin pump therapy and rapid acting insulin: what have we learned?
    Zinman B
    Int J Clin Pract Suppl; 2001 Sep; (123):47-50. PubMed ID: 11594299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical guidelines on the use of insulin lispro in elderly diabetic patients.
    Benbarka MM; Prescott PT; Aoki TT
    Drugs Aging; 1998 Feb; 12(2):103-13. PubMed ID: 9509289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Humalog® 200 U/ml KwikPen™].
    Scheen AJ
    Rev Med Liege; 2015 Oct; 70(10):527-31. PubMed ID: 26727843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    J Diabetes Investig; 2018 Jan; 9(1):91-99. PubMed ID: 28371461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.
    Ristic S; Bates PC
    Diabetes Technol Ther; 2003; 5(1):57-66. PubMed ID: 12725708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence.
    Kaiserman K; Jung H; Benabbad I; Karges B; Polak M; Rosilio M
    Pediatr Diabetes; 2017 Mar; 18(2):81-94. PubMed ID: 27390032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.